■可穿戴式心律转复除颤器(WCD),(LifeVest,ZOLL,匹兹堡PA,USA)是一种医疗设备,旨在临时检测和治疗恶性室性心律失常。WCD远程监护功能可以评估患者的身体活动(PhA)。我们试图通过WCD评估新诊断的心力衰竭患者的PhA。
■我们收集并分析了在我们诊所接受WCD治疗的所有患者的数据。新诊断的缺血性患者,或非缺血性心肌病和严重降低的射血分数,接受WCD治疗至少连续28天,且当天依从性至少18小时的患者被纳入.
■77名患者符合分析条件。37例患者患有缺血性心脏病,40例非缺血性心脏病。进行WCD的平均天数为77.3±44.6天,平均佩戴时间为22.8±2.1小时。在前两周和最后两周之间,通过每日步数测量,患者显示出PhA显着增加(前2周的平均步数:4,952.6±3,052.7vs.最近2周的平均步骤:6,119.6±3,776.2,p值:<0.001)。在监测期结束时,观察到射血分数增加(LVEF-前:25.8±6.6%vs.LVEF后:37.5±10.6%,p<0.001)。EF的改善与PhA的改善无关。
■WCD提供关于患者PhA的有用信息,并且可以另外用于早期心力衰竭治疗调整。
UNASSIGNED: The wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the patients. We sought to assess with the WCD the PhA of patients with newly diagnosed heart failure.
UNASSIGNED: We collected and analyzed the data of all patients treated with the WCD in our clinic. Patients with newly diagnosed ischemic, or non-ischemic cardiomyopathy and severely reduced ejection fraction, who were treated with the WCD for at least 28 consecutive days and had a compliance of at least 18 h the day were included.
UNASSIGNED: Seventy-seven patients were eligible for analysis. Thirty-seven patients suffered from ischemic and 40 from non-ischemic heart disease. The average days the WCD was carried was 77.3 ± 44.6 days and the mean wearing time was 22.8 ± 2.1 h. The patients showed significantly increased PhA measured by daily steps between the first two and the last two weeks (Mean steps in the first 2 weeks: 4,952.6 ± 3,052.7 vs. mean steps in the last 2 weeks: 6,119.6 ± 3,776.2, p-value: < 0.001). In the end of the surveillance period an increase of the ejection fraction was observed (LVEF-before: 25.8 ± 6.6% vs. LVEF-after: 37.5 ± 10.6%, p < 0.001). Improvement of the EF did not correlate with the improvement of PhA.
UNASSIGNED: The WCD provides useful information regarding patient PhA and may be additionally utilized for early heart failure treatment adjustment.